Yubo International Biotech Limited

YBGJOTCHealthcare● Active

$0.01

+$0.00(+0.00%)

Market Cap$1006454

P/E Ratio—

52W High$0.1776

52W Low$0.0079

Avg Volume2K

Open$0.01

Beta0.64

Overview

Yubo International Biotech Limited (YBGJ) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

YBGJ · free cash flow · updated Jun 15, 2026

Core FCF metrics

YBGJ · FCF · TTM · margin & CAGR

Free cash flow was −$842,802 for FY2025 (fiscal year ending 2025-12-31), up 37.0% year-over-year The FCF margin was -627.1%.

FY2025 Free Cash Flow−$842,802▲ +37.0% YoY

Trailing 12M (TTM)−$243,212trailing 4 quarters sum

FCF Margin-627.1%−$842,802 ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

YBGJ · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$842,802(0M)−$842,802▲ +37.0%-627.1%

FY2024−$1.3M(0M)−$1.3M▼ 4800.2%—

FY2022$68,233(0M)$28,461▲ +101.8%27.3%

FY2021−$1.0M(1M)−$1.6M▼ 43671.8%-127.4%

FY2020$101,107(0M)$3,639▲ +111.4%0.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

YBGJ · P/FCF · FCF yield · FCF per share

Yubo International Biotech Limited (YBGJ) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

YBGJ · cash flow statement · operating / investing / financing

For FY2025, Yubo International Biotech Limited generated −$0.8M in operating cash flow and spent 0M in capital expenditures, yielding −$0.8M in free cash flow.

Operating Activities

−$0.8M

Cash from core business operations

2025-12-31

Investing Activities

+$0.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$0.8M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$0.8M) − |CapEx| (0M) = FCF (−$0.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

YBGJ vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Yubo International Biotech LimitedYOU

YBGJ

−$842,802+37.0%-627.1%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Yubo International Biotech Limited (YBGJ) reported free cash flow of −$842,802 for FY2025 (fiscal year ending 2025-12-31), up 37.0% year-over-year. The FCF margin was -627.1%.

Based on available data, Yubo International Biotech Limited has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $28,461 in FY2022.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

YBGJ free cash flow · 8 questions

Yubo International Biotech Limited free cash flow was −$842,802 for FY2025, up 37.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$243,212.

YBGJ free cash flowYBGJ FCFYBGJ FCF 2025YBGJ free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Yubo International Biotech Limited · Yubo International Biotech Limited SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026